CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
EPIMAC focuses on leveraging epigenetic mechanisms to develop new therapies for Inflammatory Bowel Disease (IBD). The project aims to educate scientists in genetics and pharmacology while exploring the potential of epigenetic modifications to improve treatment outcomes for this chronic condition.
Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues.
Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting mi…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Netherlands, Utrecht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Amsterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
—
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
